Autopsy report · NCT02963064

JSP191 Antibody Targeting Conditioning in SCID Patients

“Sponsor Decision - terminated due to changes in company priorities and not related to safety concerns.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 5 months before it started.
• Ran for about 8 years 4 months before it stopped.
• 23 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1, Phase 2

Sponsor

Jasper Therapeutics, Inc.

Sponsor type

Industry

Conditions

SCID

Interventions

Humanized anti-CD117 Monoclonal Antibody (JSP191)

Participants

23

Sites

9

Countries

United States

Trials that died the same way

• Long-Chain Fatty Acid Oxidation Disorders Online Disease Monitoring Program
  “Sponsor decision not related to safety concerns” (82% match in meaning)
• Effect of Lixisenatide on Postprandial Lipid Profile in Obese Type 2 Diabetic Patients
  “Sponsor decision not related to safety reasons” (82% match in meaning)
• REGENETEN™ Bioinductive Implant System in Full-thickness Tears
  “Sponsor decision not related to safety.” (81% match in meaning)
• Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
  “Sponsor decision; the decision is not related to any safety concern.” (80% match in meaning)
• Assessing the Clinical Benefit of Molecular Profiling in Patients With Solid Tumors
  “Sponsor's discretion to termination due to business decision.” (78% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.